Siren, L.L.C. Trevi Therapeutics, Inc. Transaction History
Siren, L.L.C.
- $1.76 Trillion
- Q1 2025
A detailed history of Siren, L.L.C. transactions in Trevi Therapeutics, Inc. stock. As of the latest transaction made, Siren, L.L.C. holds 2,863,793 shares of TRVI stock, worth $21.2 Million. This represents 1.03% of its overall portfolio holdings.
Number of Shares
2,863,793
Previous 2,906,060
1.45%
Holding current value
$21.2 Million
Previous $12 Billion
50.45%
% of portfolio
1.03%
Previous 0.53%
Shares
2 transactions
Others Institutions Holding TRVI
# of Institutions
150Shares Held
85.5MCall Options Held
1.51MPut Options Held
304K-
Nea Management Company, LLC Timonium, MD11.4MShares$84.4 Million6.78% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA10.3MShares$76.1 Million4.06% of portfolio
-
Rubric Capital Management LP New York, NY4.54MShares$33.7 Million0.82% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.84MShares$28.5 Million0.0% of portfolio
-
Vivo Capital, LLC Palo Alto, CA3.49MShares$25.9 Million5.95% of portfolio
About Trevi Therapeutics, Inc.
- Ticker TRVI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,322,500
- Market Cap $433M
- Description
- Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritu...